Work

The clinical impact of an altered endogenous carnitine profile

Year: 2011
Type: dissertation
Study design: Observational Study
Abstract: Carnitine is an endogenous compound found in all mammalian species.The most important biological function of carnitine is in the transport of fatty acids into the mitochondria for β-oxidation, a process which involves the esterification of carnitine to acylcarnitine derivatives via carnitine palmitoyltransferase.In addition to its role in mitochondrial fatty acid oxidation, it has been established that carnitine has critical functions in the transport of short-and medium-chain acyl groups from the peroxisome to the mitochondria, in the removal of excess acyl groups from the body as well as in the modulation of intracellular coenzyme A homeostasis such that alterations in the ratio of acylcarnitine to (free) L-carnitine is reflective of disturbed mitochondrial metabolism.Carnitine deficiency has been associated with a number of conditions, either the result of disturbances in the dietary intake, biosynthesis, distribution, elimination or utilisation of carnitine.Despite widespread research examining altered L-carnitine levels in these conditions, relatively few studies have examined the involvement of acylcarnitines.Therefore, the overall aim of this project was to determine the clinical impact of an altered endogenous carnitine profile, in particular with respect to the relative contribution of L-carnitine and its ester derivatives to the composition of the carnitine pool and its involvement in disorders of carnitine insufficiency, specifically end-stage renal disease patients undergoing long-term haemodialysis treatment and patients with chronic fatigue syndrome.While there has been extensive research which has established that chronic haemodialysis treatment results in low endogenous L-carnitine levels, this project, using data from healthy subjects as a reference, was able to demonstrate that end-stage renal disease patients undergoing long-term haemodialysis treatment also exhibit substantially elevated mediumand long-chain acylcarnitine concentrations.This is due, at least in part, to their limited removal by the haemodialysis procedure, most likely a result of the increased molecular weight, lipophilicity and protein-binding that accompanies increased chain-length of the acyl group.Consequently, the composition of the endogenous plasma carnitine pool is considerably altered in this patient group compared to that observed in healthy controls.These alterations in carnitine pool composition were shown to be significantly related to the severity/incidence of a number of dialysis-related disorders commonly reported in this patient population, including erythropoietin-resistant anaemia, muscle fatigue, cardiac dysfunction, muscle cramps and intradialytic hypotension with a more greatly disturbed carnitine profile associated with more severe symptomology.It is proposed that the accumulation of acylcarnitines and deficiency of L-carnitine in these patients results in decreased activity of carnitine palmitoyltransferase which ultimately leads to impaired acyl group utilisation resulting in symptomology. Summary P a g e | ixThe involvement of altered carnitine homeostasis in chronic fatigue syndrome is less well defined.This project was able to demonstrate that while chronic fatigue syndrome is not associated with alterations in endogenous L-carnitine concentrations, patients exhibit significantly lower levels of long-chain acylcarnitines, in particular oleyl-L-carnitine and linoleyl-L-carnitine, than healthy controls.These altered acylcarnitine levels were significantly correlated to fatigue severity, such that patients with lower long-chain acylcarnitine levels exhibited more severe fatigue symptoms.Previous research has established that chronic fatigue syndrome patients exhibit elevated levels of fatty acids that correspond to these deficient acylcarnitines, thus it is proposed that chronic fatigue syndrome is associated with impaired utilisation of fatty acids, most likely due to decreased carnitine palmitoyltransferase activity; the underlying cause of this is unknown.
Language: English
Open Access status: green
OpenAlex ID: W7222377951
Cites: 382
Cited by:
Related to: 10